Interim results from a first-in-human phase I clinical trial evaluating the safety, antitumor activity, and immunological characteristics of a genetically engineered natural killer T-cell immunotherapy for neuroblastoma showed that the treatment was well tolerated. Researchers also observed early evidence of strong antitumor activity.
Adding CD28 costimulation to cord blood-derived chimeric antigen receptor natural killer cells targeting CD70+ cancers significantly enhanced antitumor efficacy and long-term cytotoxicity of the CAR NK cells, according to researchers from MD Anderson Cancer Center.
